The term '11q23 abnormalities' was originally used to describe various morphological changes of the terminal part of chromosome 11q that are evident on the cytogenetic level only. However, following the adoption of this term by molecular biologists and clinicians, it is now used to denote all genetic alterations that are encountered within this region regardless of the method of their ascertainment. Chromosome band 11q23 is the site of the mixed lineage leukemia (MLL) gene that is most often disrupted in 11q23 abnormalities of various hematological neoplasms. Although 11q23/MLL aberrations are usually recognized as being reciprocal on the chromosomal level, few could nevertheless be interpreted as an unbalanced rearrangement or deletion. Thus, apart from its value to detect virtually all MLLinvolving rearrangements on a single-cell level, dual-color fluorescence in situ hybridization (FISH) analysis with 3 0 and 5 0 MLL split-apart probes is also very helpful to discover cases with either 3 0 MLL or even complete MLL deletions. 1 Genetic abnormalities involving the 11q23/MLL region account for about 5-10% of childhood acute lymphoblastic leukemia (ALL). Patients with an 11q23 deletion in which an entire MLL allele may or may not be eliminated account for approximately 20% of the 11q23-rearranged cases. 2, 3 Although there are limited data on the biological and clinical characteristics as well as the prognosis of a del(11)(q23) in pediatric ALL, a few previous studies showed that this abnormality was commonly associated with low-risk features at presentation and survival rates of approximately 75%. 2, 3 The detection of several cases with such 11q deletions during our screening program for secondary genetic abnormalities in ETV/RUNX1 þ B-cell precursor (BCP) ALL led us assess the incidence as well as the clinical, laboratory and biological features of 11q23-deleted cases in a population-based cohort of consecutively registered BCP ALL patients. 4 Between 22 September 1986 and 31 May 2005, 948 previously untreated children and adolescents up to 18 years of age diagnosed with ALL were enrolled in four consecutive multicenter trials of the Berlin-Frankfurt-Mü nster (BFM) group: ALL-BFM-A (Austria) 1986 (n ¼ 142), ALL-BFM-A 1990 (n ¼ 256), ALL-BFM-A 1995 (n ¼ 230) and ALL-BFM-A 2000 (n ¼ 312). 5 From 1999 onward, infants with ALL were enrolled in trial INTERFANT-A 1999 (n ¼ 8). ALL was diagnosed according to standard morphological, cytochemical and immunophenotypic criteria. All cases were reviewed by the National Study Center in Vienna and treated after obtaining informed consent from the patients, patient's parents or legal guardians. Out of the 948 patients, 824 (87%) had a B-lineage ALL and 122 (13%) a T-lineage ALL. Two patients had an acute undifferentiated leukemia with FAB L1/L2 morphology. Cytogenetic analyses were performed centrally and results were classified according to the guidelines of the International System for Human Cytogenetic Nomenclature (ISCN) 1995. ETV6/ RUNX1 and MLL FISH analyses were also carried out centrally according to standard procedures. 1, 4 Among the 673/824 (82%) patients with B-lineage ALL who had cytogenetic data available, we identified 27 (4%) cases with 11q23 abnormalities (Table 1) . They included 12 patients (44%) with a t(4;11)(q21;q23), four patients (15%) with a t(11;19)(q23;p13), eight patients (30%) with a del(11)(q23) and one patient each with a t(9;11)(p22;q23), a t(1;11)(q32;q23) and a t(1;9;11;19)(q21;p13;q12q23;p13). All eight patients with a del(11)(q23) showed a good prednisone response with less than 1000/ml blast cells in peripheral blood on day 8 after a 7-day treatment with prednisone and one intrathecal dose of methotrexate on day 1. Bone marrow (BM) at day 15 was evaluated in seven of the eight patients, demonstrating M1 BM in three and M2 BM in four cases. All patients achieved a complete remission by day 33.
The eight patients with a del(11)(q23) were found to be significantly associated with an age of 1-10 years (P ¼ 0.002), low white blood cell (WBC) counts (Po0.001) and a CD10 þ BCP immunophenotype (Po0.001), as compared to the 17 patients with 11q23/MLL translocations. The two patients with a t(1;11) and a t(1;9;11;19) had not been included in this analysis as FISH analysis disclosed the lack of a MLL-involving translocation. Out of the eight patients with a del(11)(q23), only one suffered from a relapse and that occurred 4.13 years after primary diagnosis and was localized to the right ovary only. The patient is now in continuous remission after secondline chemotherapy. Another patient developed a secondary MLL-rearranged AML 4.50 years after ALL diagnosis. This patient was rescued with a high-dose regimen followed by bone marrow transplantation from a matched-unrelated donor.
After a median follow-up of 8.15 years (range 0.83-17.67 years), the 8-year probabilities of event-free and relapse-free survival were 69719 and 86713% for the eight patients with a del(11)(q23). In comparison, both the 8-year probability of event-free and relapse-free survival were 52712% for the 17 patients with 11q23/MLL translocations (P ¼ 0.22; P ¼ 0.09). The 8-year probability of survival was 100 and 76710% for the two patient cohorts studied (P ¼ 0.16). There was also no significant difference in the early response to therapy at day 8 and day 15 between the patients with a del(11)(q23) and cases with 11q23/ MLL translocations.
In five of the eight patients, the 11q23 deletion was the only cytogenetically visible abnormality (Table 2 ). FISH analysis showed that seven of the eight patients with a del(11)(q23) had an ETV6/RUNX1 rearrangement. MLL FISH analysis disclosed that out of the seven patients with adequate material, six had a complete deletion of one MLL allele. Owing to the lack of appropriate material, the presence of a MLL rearrangement in the only ETV6/RUNX1À patient with a del (11) þ patients with (n ¼ 7) and without (n ¼ 158) a del(11)(q23) revealed no significant difference regarding 8-year event-free (67719 vs 8773%, P ¼ 0.17) and overall survival (100 vs 9472%, P ¼ 0.56).
Childhood BCP ALL cases with a del(11)(q23) are so far considered to comprise an ill-defined, biologically and clinically heterogeneous group of patients. Although their presenting features and prognosis have been found to be more favorable as compared to patients with 11q23/MLL rearrangements, they are nevertheless always grouped together with the latter ones for the evaluation of the overall outcome of patients with 11q23 aberrations. 6 The results of our analysis primarily give compelling evidence that cases with a del(11)(q23) constitute in fact a distinct subentity among ETV6/RUNX1 þ BCP ALL. This finding thereby also provides a simple explanation for their favorable clinical features at initial diagnosis as well as for their good prognosis. Thus, del(11)(q23) merely represents a highly specific nonrandom secondary genetic abnormality that should always alert to the potential presence of an ETV6/RUNX1-associated t(12;21)(p13;q22) that is rarely identified with conventional cytogenetic means only. Other such specific cytogenetic indicators for a cryptic t(12;21) are deletions of 12p and duplications of the normal or derivate chromosome 21, as well as near-tetraploidy. 4 However, the virtually exclusive and similar association of a del(11)(q23) with the ETV6/RUNX1 fusion gene has so far not been fully realized.
Although there was a trend towards a better prognosis in cases with 11q23 deletions, probably owing to the relatively small number of patients included in our study, there was no statistically significant difference in the survival rates between patients with a del(11)(q23) and cases with 11q23/MLL translocations. Nevertheless, this trend may simply reflect the fact that the 11q23-deleted patients are mostly ETV6/RUNX1 þ , a well-known favorable factor in childhood BCP ALL. Thus, del(11)(q23) seems to have no prognostic meaning per se and, unlike its presence in adult chronic lymphoblastic leukemia (CLL), certainly has at least no adverse impact on prognosis. 7 Whether the diverse biological consequences of a del(11)(q23) in these two types of leukemia depend on the particular cellular and genetic context, or whether they result from genetic lesions that affect different chromosomal regions remains to be investigated. However, only a single study has yet tried to characterize the del(11)(q23) aberration in more detail, albeit by screening an unselected group of BCP ALL patients for the loss of heterozygosity (LOH). 8 The short report of Takeuchi et al. 8 demonstrated that 18 of 113 ALL (16%) patients included in trial ALL-BFM 90 had LOH at least at one locus of 11q. They identified three distinct regions of deletion, two containing the MLL and one the ATM gene. Patient with extramedullary relapse in the right ovary.
Letters to the Editor
Whether BCP ALL cases with a del(11)(q23) are discovered or not has several important practical implications, particularly regarding the comparison of incidence rates and treatment outcome of the group of patients with 11q23 abnormalities between different therapy studies. The detection of cases with a del(11)(q23) obviously depends on the diagnostic procedures that are pursued in a clinical study as conventional cytogenetics or MLL FISH screening (that will independently reveal classic MLL translocations) will identify them, whereas screening solely for ETV6/RUNX1 with FISH or RT-PCR will miss them. Thus, the respective screening approach will not only determine the actual incidence rates of 11q23/ MLL abnormalities but also influence the overall and, in particular, the age-specific survival rates in this group of patients. As can be deduced from the results of our analysis, the inclusion or exclusion of such cases is certainly relevant, especially when considering that cases with a del(11)(q23) constitute, as shown herein, approximately one-third of all 11q23 abnormalities. Moreover, as virtually all cases appear to be ETV6/RUNX1 þ , they do not only belong to a very favorable genetic ALL subset that is mainly enrolled into the lower risk groups but also to a more favorable age group that in any case has a better prognosis, even in the 11q23 abnormality group itself.
Our finding that del(11)(q23) is a nonrandom and highly specific secondary aberration in ETV6/RUNX1
þ BCP ALL rather than a disease-relevant primary abnormality provides substantial evidence that among ALL cases with 11q23 abnormalities it constitutes a highly distinct and separate entity. Based thereon, we suggest that in future clinical ALL studies, cases with a cytogenetically evident del(11)(q23) may not anymore be evaluated together with the 11q23/MLL translocations, but in the first instance, screened for the ETV6/RUNX1 fusion gene. Lenalidomide (Revlimid) is an immunomodulatory drug that yields a high frequency of erythroid, pathologic, and cytogenetic response in patients with myelodysplastic syndromes (MDS) with an interstitial deletion of the long arm of chromosome 5 (del 5q). We report here the case of a patient with acute myeloid leukemia (AML) (acute panmyelosis with myelofibrosis) with chromosome 5q deletion who achieved a complete hematologic and cytogenetic remission with lenalidomide treatment.
Treatment of deletion 5q acute myeloid leukemia with lenalidomide
A previously healthy 55-year-old female presented in September 2005 with shortness of breath and severe fatigue.
Her physical exam was unremarkable, including a lack of palpable hepatosplenomegaly. Laboratory data revealed white blood cells (WBC) count 3.8 k/ul, hemoglobin (Hb) of 6.4 g/dl, and platelet count 381 k/ul. Inspection of the peripheral blood film revealed no leukoerythroblastic features. A bone marrow biopsy performed on 26 September 2005 (Figure 1a ) revealed 60% cellularity, atypical megakaryocytic hyperplasia, along with markedly increased reticulin fibrosis. No increased number of myeloblasts was detected. Cytogenetic studies were not performed. The patient was managed conservatively with weekly erythropoietin injections and red blood cell transfusions every 2-3 weeks. Over the subsequent months, she developed progressive thrombocytopenia accompanying the transfusiondependent anemia. On 16 December 2005, the platelet count was 84 k/ul, and a repeat bone marrow aspirate and biopsy
